The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.
 
Willemijn Theelen
No Relationships to Disclose
 
No Firstname H.Peulen@Nki.Nl
No Relationships to Disclose
 
Ferry Lalezari
No Relationships to Disclose
 
Jeltje de Vries
No Relationships to Disclose
 
Joop De Langen
No Relationships to Disclose
 
Joachim Aerts
Stock and Other Ownership Interests - amphera
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Roche
Speakers' Bureau - AstraZeneca
Patents, Royalties, Other Intellectual Property - cdendritic cel based immunotherapy (Inst); proteomics in nsclc (Inst)
 
Kim Monkhorst
No Relationships to Disclose
 
Paul Baas
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
Other Relationship - Bristol-Myers Squibb